drugset
drugset / Trial / NCT05694533

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

NCT05694533 ↗

Phase 1 Completed 20 enrolled Indivior Inc. National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.

Timeline

Start
2023-03-16
Primary completion
2023-04-06
Completion
2023-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INDV-2000 Unknown — Oral
Subject Midazolam Small molecule — Oral

Indications

No indication recorded.